| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$7.8M | ROE | −170.73% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $6.3M | Trading Days | 2007 |
| 52W High | 19.00 |
| 52W Low | 1.31 |
| % Off High | −84.47% |
| YTD | −46.36% | 1Y | −81.27% |
| 3Y | −98.25% | 5Y | −99.80% |
| Since incept. (ann.) | −57.00% |
| Ann. Volatility (1Y) | 88.63% | Ann. Volatility (3Y) | 142.20% |
| Sharpe (1Y) | −1.48 | Sharpe (3Y) | −0.37 |
| Max Drawdown (1Y) | −91.37% | Max Drawdown (3Y) | −99.32% |
| Beta (3Y, vs SPY) | 1.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ALZN | Alzamend Neuro, Inc. | $6.3M | — |
| IMNN | Imunon, Inc. | $6.4M | — |
| PULM | Pulmatrix, Inc. | $6.1M | — |
| KAPA | Kairos Pharma, LTD. | $6.6M | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.1M | — |
| AEON | AEON Biopharma, Inc. | $6.7M | — |
| CVKD | Cadrenal Therapeutics, Inc. | $5.8M | — |
| XBIO | Xenetic Biosciences, Inc. | $5.7M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. |
| $5.5M |
| — |
| MTVA | MetaVia Inc. | $7.4M | — |
